Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
References Sikiric P, Seiwerth S, et al
Use only in properly equipped laboratory settings with appropriate personal protective equipment.
NAD Preservation: Supports higher intracellular NAD availability, promoting mitochondrial function and cellular energy production
Its key to have a doctor watch over you
A single dose of Vitamin B12 provides immediate benefits to those experiencing a deficiency